| review article | Q7318358 |
| scholarly article | Q13442814 |
| P2093 | author name string | Hiroyasu Sato | |
| Kei Yamamoto | |||
| Makoto Murakami | |||
| Yoshitaka Taketomi | |||
| Yuki Isogai | |||
| P2860 | cites work | Group X Secretory Phospholipase A 2 Negatively Regulates ABCA1 and ABCG1 Expression and Cholesterol Efflux in Macrophages | Q24299933 |
| Macrophage secretory phospholipase A2 group X enhances anti-inflammatory responses, promotes lipid accumulation, and contributes to aberrant lung pathology | Q24317282 | ||
| Disruption of the 12/15-lipoxygenase gene diminishes atherosclerosis in apo E-deficient mice | Q24563208 | ||
| Structure-based design of the first potent and selective inhibitor of human non-pancreatic secretory phospholipase A2 | Q27729874 | ||
| Cloning, chromosomal mapping, and expression of a novel human secretory phospholipase A2 | Q28115215 | ||
| Inflammation and atherosclerosis: Group IIa and Group V sPLA2 are not redundant | Q28247981 | ||
| Binding of human phospholipase A2 type II to proteoglycans. Differential effect of glycosaminoglycans on enzyme activity | Q28291085 | ||
| Secretory phospholipase A2-IID is an effector molecule of CD4+CD25+ regulatory T cells | Q28512213 | ||
| Neuronal expression and neuritogenic action of group X secreted phospholipase A2 | Q28577991 | ||
| Inflammation in atherosclerosis | Q29547428 | ||
| The pathogenesis of atherosclerosis: a perspective for the 1990s | Q29547827 | ||
| Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity | Q29617216 | ||
| Lysophosphatidylcholine: a chemotactic factor for human monocytes and its potential role in atherogenesis | Q33567912 | ||
| Minimally modified low density lipoprotein induces monocyte chemotactic protein 1 in human endothelial cells and smooth muscle cells | Q33667974 | ||
| Bioactive products generated by group V sPLA(2) hydrolysis of LDL activate macrophages to secrete pro-inflammatory cytokines | Q33771533 | ||
| Circulating levels of secretory type II phospholipase A(2) predict coronary events in patients with coronary artery disease | Q33874567 | ||
| Potent modification of low density lipoprotein by group X secretory phospholipase A2 is linked to macrophage foam cell formation. | Q34129390 | ||
| New phospholipase A2 isozymes with a potential role in atherosclerosis | Q34264067 | ||
| Group V sPLA2 hydrolysis of low-density lipoprotein results in spontaneous particle aggregation and promotes macrophage foam cell formation | Q34298659 | ||
| The secretory phospholipase A2 gene is a candidate for the Mom1 locus, a major modifier of ApcMin-induced intestinal neoplasia | Q34313013 | ||
| Phospholipase A(2) in vascular disease | Q34339322 | ||
| Group X secretory phospholipase A(2) augments angiotensin II-induced inflammatory responses and abdominal aortic aneurysm formation in apoE-deficient mice | Q34422563 | ||
| Circulating secretory phospholipase A2 activity predicts recurrent events in patients with severe acute coronary syndromes | Q34455926 | ||
| Group v secretory phospholipase A2 promotes atherosclerosis: evidence from genetically altered mice | Q34598093 | ||
| A novel anti-inflammatory role for secretory phospholipase A2 in immune complex-mediated arthritis | Q34681820 | ||
| Physiological roles of group X-secreted phospholipase A2 in reproduction, gastrointestinal phospholipid digestion, and neuronal function | Q34719758 | ||
| Varespladib (A-002), a secretory phospholipase A2 inhibitor, reduces atherosclerosis and aneurysm formation in ApoE-/- mice | Q34917512 | ||
| Effects of 1-H-indole-3-glyoxamide (A-002) on concentration of secretory phospholipase A2 (PLASMA study): a phase II double-blind, randomised, placebo-controlled trial | Q34949268 | ||
| Deletion of microsomal prostaglandin E synthase-1 augments prostacyclin and retards atherogenesis. | Q35029268 | ||
| Lysophosphatidylcholine, a component of atherogenic lipoproteins, induces mononuclear leukocyte adhesion molecules in cultured human and rabbit arterial endothelial cells | Q35822759 | ||
| Secretory phospholipase A2 enzymes in atherogenesis | Q36125690 | ||
| Lysophosphatidic acid induces neointima formation through PPARgamma activation. | Q36402330 | ||
| Secretory PLA2 inhibitor indoxam suppresses LDL modification and associated inflammatory responses in TNFalpha-stimulated human endothelial cells | Q36734411 | ||
| Biochemistry and physiology of mammalian secreted phospholipases A2. | Q37135739 | ||
| Analyses of group III secreted phospholipase A2 transgenic mice reveal potential participation of this enzyme in plasma lipoprotein modification, macrophage foam cell formation, and atherosclerosis. | Q37142814 | ||
| Molecular and functional characterization of polymorphisms in the secreted phospholipase A2 group X gene: relevance to coronary artery disease | Q37238669 | ||
| Group III secreted phospholipase A2 transgenic mice spontaneously develop inflammation | Q37257483 | ||
| The capacity of group V sPLA2 to increase atherogenicity of ApoE-/- and LDLR-/- mouse LDL in vitro predicts its atherogenic role in vivo | Q37435082 | ||
| Roles of thromboxane A(2) and prostacyclin in the development of atherosclerosis in apoE-deficient mice | Q37511097 | ||
| Metabolism and atherogenic disease association of lysophosphatidylcholine | Q37537825 | ||
| Emerging roles of secreted phospholipase A2 enzymes: Lessons from transgenic and knockout mice. | Q37720258 | ||
| Phospholipase A2-modified low-density lipoprotein activates macrophage peroxisome proliferator-activated receptors | Q39769175 | ||
| Lipoprotein metabolism in the macrophage: implications for cholesterol deposition in atherosclerosis | Q40137011 | ||
| Atherogenic properties of LDL particles modified by human group X secreted phospholipase A2 on human endothelial cell function. | Q40213725 | ||
| Focused lipidomics by tandem mass spectrometry | Q40403203 | ||
| Large scale gene expression analysis of cholesterol-loaded macrophages | Q40856774 | ||
| Minimal oxidation and storage of low density lipoproteins result in an increased susceptibility to phospholipid hydrolysis by phospholipase A2. | Q41098668 | ||
| Role of group II secretory phospholipase A2 in atherosclerosis: 1. Increased atherogenesis and altered lipoproteins in transgenic mice expressing group IIa phospholipase A2. | Q41664283 | ||
| The synergistic inhibition of atherogenesis in apoE-/- mice between pravastatin and the sPLA2 inhibitor varespladib (A-002). | Q41814827 | ||
| Role of group IIa and group V secretory phospholipases A(2) in the metabolism of lipoproteins. Substrate specificities of the enzymes and the regulation of their activities by sphingomyelin | Q43951795 | ||
| Identification of 5-lipoxygenase as a major gene contributing to atherosclerosis susceptibility in mice | Q44079670 | ||
| Macrophage-expressed group IIA secretory phospholipase A2 increases atherosclerotic lesion formation in LDL receptor-deficient mice | Q44316915 | ||
| Subtype-selective antagonists of lysophosphatidic Acid receptors inhibit platelet activation triggered by the lipid core of atherosclerotic plaques | Q44529184 | ||
| Group V and X secretory phospholipase A(2)s-induced modification of high-density lipoprotein linked to the reduction of its antiatherogenic functions | Q44628275 | ||
| Lysophosphatidylcholine regulates human microvascular endothelial cell expression of chemokines | Q44641329 | ||
| Rapid and selective identification of molecular species in phosphatidylcholine and sphingomyelin by conditional neutral loss scanning and MS3. | Q45164007 | ||
| Indole inhibitors of human nonpancreatic secretory phospholipase A2. 1. Indole-3-acetamides | Q46259343 | ||
| Accelerated glucose intolerance, nephropathy, and atherosclerosis in prostaglandin D2 synthase knock-out mice | Q46560412 | ||
| Differential hydrolysis of molecular species of lipoprotein phosphatidylcholine by groups IIA, V and X secretory phospholipases A2. | Q46669673 | ||
| Increased lipolysis by secretory phospholipase A(2) group V of lipoproteins in diabetic dyslipidaemia | Q46734947 | ||
| Minimally oxidized low-density lipoprotein increases expression of scavenger receptor A, CD36, and macrosialin in resident mouse peritoneal macrophages | Q46788121 | ||
| Distinct mechanisms for OxLDL uptake and cellular trafficking by class B scavenger receptors CD36 and SR-BI. | Q50337554 | ||
| Group V secretory phospholipase A2-modified low density lipoprotein promotes foam cell formation by a SR-A- and CD36-independent process that involves cellular proteoglycans. | Q50760094 | ||
| Transgenic expression of group V, but not group X, secreted phospholipase A2 in mice leads to neonatal lethality because of lung dysfunction. | Q52005910 | ||
| Tagging SNP haplotype analysis of the secretory PLA2-V gene, PLA2G5 , shows strong association with LDL and oxLDL levels, suggesting functional distinction from sPLA2-IIA: results from the UDACS study | Q61560054 | ||
| Lipolysis of LDL by Human Secretory Phospholipase A 2 Induces Particle Fusion and Enhances the Retention of LDL to Human Aortic Proteoglycans | Q62023748 | ||
| Localization of nonpancreatic secretory phospholipase A2 in normal and atherosclerotic arteries. Activity of the isolated enzyme on low-density lipoproteins | Q73178565 | ||
| Molecular basis for the association of group IIA phospholipase A(2) and decorin in human atherosclerotic lesions | Q73623179 | ||
| Ultrastructural localization of secretory type II phospholipase A2 in atherosclerotic and nonatherosclerotic regions of human arteries | Q74471855 | ||
| Lipoproteins are substrates for human secretory group IIA phospholipase A2: preferential hydrolysis of acute phase HDL | Q77502915 | ||
| Hydrolysis of minor glycerophospholipids of plasma lipoproteins by human group IIA, V and X secretory phospholipases A2 | Q79465569 | ||
| Expression of secretory phospholipase A2s in human atherosclerosis development | Q79922608 | ||
| A randomized, double-blinded, placebo-controlled clinical trial of LY333013, a selective inhibitor of group II secretory phospholipase A2, in the treatment of rheumatoid arthritis | Q81463176 | ||
| Secretory phospholipase A2 group V: lesion distribution, activation by arterial proteoglycans, and induction in aorta by a Western diet | Q83118082 | ||
| Varespladib methyl, an oral phospholipase A2 inhibitor for the potential treatment of coronary artery disease | Q84443730 | ||
| P433 | issue | 7 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | enzyme | Q8047 |
| lipid | Q11367 | ||
| lipoprotein | Q28350 | ||
| atherosclerosis | Q12252367 | ||
| P304 | page(s) | 1829-1842 | |
| P577 | publication date | 2011-03-29 | |
| 2011-06-01 | |||
| P1433 | published in | Analytical and Bioanalytical Chemistry | Q2845280 |
| P1476 | title | Secreted phospholipase A2, lipoprotein hydrolysis, and atherosclerosis: integration with lipidomics | |
| P478 | volume | 400 |
| Q42402758 | Effect of surfactant hydrophobicity on the pathway for unfolding of ubiquitin |
| Q92578258 | Group IID, IIE, IIF and III secreted phospholipase A2s |
| Q39581478 | Identification of human plasma metabolites exhibiting time-of-day variation using an untargeted liquid chromatography-mass spectrometry metabolomic approach. |
| Q35590666 | In vitro anti-Plasmodium falciparum properties of the full set of human secreted phospholipases A2. |
| Q34047043 | Leptin reverts pro-apoptotic and antiproliferative effects of α-linolenic acids in BCR-ABL positive leukemic cells: involvement of PI3K pathway |
| Q42254437 | Lipidomic profiling of plasma in patients with chronic hepatitis C infection |
| Q48054989 | Mass-spectrometry-based lipidomics. |
| Q47128368 | Metabolic regulation by secreted phospholipase A2. |
| Q77791762 | Redox (phospho)lipidomics of signaling in inflammation and programmed cell death |
| Q35764402 | Systematic Review of the Association between Lipoprotein-Associated Phospholipase A2 and Atherosclerosis |
| Q36180657 | The role of group IIF-secreted phospholipase A2 in epidermal homeostasis and hyperplasia |
Search more.